Neurohumoral Effects of Aliskiren in Patients With Symptomatic Heart Failure Receiving a Mineralocorticoid Receptor Antagonist: The Aliskiren Observation of Heart Failure Treatment Study

European Journal of Heart Failure - United States
doi 10.1093/eurjhf/hfr034
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Effects of Mineralocorticoid Receptor Antagonist Spironolactone on Atrial Conduction and Remodeling in Patients With Heart Failure

Journal of Cardiology
Cardiovascular MedicineCardiology
2011English

Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure

JAMA - Journal of the American Medical Association
Medicine
2015English

Mineralocorticoid Receptor Antagonists for Heart Failure

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2011English

Neurohumoral Pathway in Heart Failure

ACI (Acta Cardiologia Indonesiana)
2019English

Tailoring Mineralocorticoid Receptor Antagonist Therapy in Heart Failure Patients: Are We Moving Towards a Personalized Approach?

European Journal of Heart Failure
Cardiovascular MedicineCardiology
2017English

Mineralocorticoid Receptor Antagonists for Heart Failure: A Real-Life Observational Study

ESC heart failure
Cardiovascular MedicineCardiology
2018English

Short-Term Oral Endothelin-Receptor Antagonist Therapy in Conventionally Treated Patients With Symptomatic Severe Chronic Heart Failure

Circulation
Cardiovascular MedicinePhysiologyCardiology
1998English

Treatment of Patients With Heart Failure.

Circulation
Cardiovascular MedicinePhysiologyCardiology
1990English

Echocardiographic Changes With Mineralocorticoid Antagonists in Heart Failure

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy